


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Denicimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Novo Nordisk (Denecimig [Mim8])	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Gene PeopleGenetic Alliance UK	 Board of Community Health Councils in Wales
Haemophilia Society	British National Formulary
South Asian Health Foundation	Care Quality Commission
Specialised Healthcare Alliance	Department of Health - Northern IrelandHaemophilia Scotland
Healthcare professional groups	Haemophilia Wales
Association of Genetic Nurses &	Healthcare Improvement Scotland
Counsellors	Hospital Information Services -
British Blood Transfusion Society	Jehovah's Witnesses
British Geriatrics Society	Medicines and Healthcare products
British Society for Genetic Medicine	Regulatory Agency
British Society for Haematology	 National Association of Primary Care
Haemophilia Nurses Association	National Pharmacy Association
Neonatal and Paediatric Pharmacists	NHS Confederation
Group	NHS Wales Joint Commissioning
Royal College of General Practitioners	Committee
Royal College of Nursing	Scottish Medicines Consortium
Royal College of Paediatrics & Child Health	Welsh Government
Royal College of Pathologists	Possible comparator companies
Royal College of Physicians	Roche (Emicizumab)
Royal Pharmaceutical Society	Swedish Orphan Biovitrum
Royal Society of Medicine	(Efanesoctocog alfa)
UK Clinical Pharmacy Association	
UK Haemophilia Centre Doctors'	
Organisation	
	Relevant research groups
<u>Others</u>	Cochrane Haematology
Department of Health and Social Care	Genomics England
NHS England	MRC Clinical Trials Unit
	National Institute for Health Research



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	Associated Public Health groups
	Public Health Wales
	UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.